カテゴリ： Allied Market Research, 世界, 医療/バイオ

オランザピンのグローバル市場（2021〜2031）：統合失調症、双極性障害、その他

■ 英語タイトル：Olanzapine Market By Application (Schizophrenia, Bipolar Disorder, Others), By Route of Administration (Oral, Parenteral), By Distribution Channel (Hospital Pharmacies, Drug stores and Retail Pharmacies, Online Providers): Global Opportunity Analysis and Industry Forecast, 2021-2031

調査会社Allied Market Research社が発行したリサーチレポート（データ管理コード：ALD23FB147）■ 発行会社/調査会社：Allied Market Research
■ 商品コード：ALD23FB147
■ 発行日：2022年10月
■ 調査対象地域：グローバル
■ 産業分野：医薬品
■ ページ数：229
■ レポート言語：英語
■ レポート形式：PDF
■ 納品方式：Eメール（受注後24時間以内）
■ 販売価格オプション（消費税別）
Online Only（1名閲覧、印刷不可）USD3,570 ⇒換算￥542,640見積依頼/購入/質問フォーム
Single User（1名閲覧）USD5,730 ⇒換算￥870,960見積依頼/購入/質問フォーム
Enterprise User（閲覧人数無制限）USD9,600 ⇒換算￥1,459,200見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能）
※Allied Market Research社の概要及び新刊レポートはこちらでご確認いただけます。
★グローバルリサーチ資料[オランザピンのグローバル市場（2021〜2031）：統合失調症、双極性障害、その他]についてメールでお問い合わせはこちら
*** レポート概要（サマリー）***

Allied Market Research社の本市場調査レポートは、世界のオランザピン市場を総合的に調査・分析した資料であり、イントロダクション、エグゼクティブサマリー、市場概要、用途別（統合失調症、双極性障害、その他）分析、投与経路別（経口、非経口）分析、流通チャネル別（病院薬局、ドラックストア・小売薬局、オンライン供給者）分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米・中東・アフリカ）分析、企業状況、企業情報などを掲載しています。また、本レポートは、Alkermes, Inc.、apotex inc.、Aurobindo Pharma Ltd、Eli Lilly and Company、Dr. Reddy's Laboratories Ltd.、Sun Pharmaceutical Industries Limited、Torrent Group、Teva Pharmaceutical Industries Limited、Novartis AG、Viatrisなどの企業情報を含んでいます。
・イントロダクション
・エグゼクティブサマリー
・市場概要
・世界のオランザピン市場規模：用途別
- 統合失調症における市場規模
- 双極性障害における市場規模
- その他における市場規模
・世界のオランザピン市場規模：投与経路別
- 経口投与における市場規模
- 非経口投与における市場規模
・世界のオランザピン市場規模：流通チャネル別
- 病院薬局チャネルの市場規模
- ドラッグストア・小売薬局チャネルの市場規模
- オンライン供給者チャネルの市場規模
・世界のオランザピン市場規模：地域別
- 北米のオランザピン市場規模
- ヨーロッパのオランザピン市場規模
- アジア太平洋のオランザピン市場規模
- 中南米・中東・アフリカのオランザピン市場規模
・企業状況
・企業情報

オランザピンは非定型抗精神病薬で、主に統合失調症や双極性障害の治療に用いられます。錠剤、注射剤、崩壊錠があります。ドーパミンとセロトニンのバランスをとり、認知、気分、行動を高めます。オランザピンは、13歳以上の成人および10代の若者における、思考障害や奇妙な思考、生活への興味の喪失、強い感情や不適切な感情を引き起こす精神疾患である統合失調症の症状の治療に使用されます。また、双極性障害の治療にも使用されます。双極性障害は、躁うつ病であり、13歳以上の成人および青少年において、躁、悲しみ、その他の異常な気分のエピソードが生じる疾患です。

世界保健機関（WHO）は、加盟国のメンタルヘルスを促進し、精神障害を予防するためのメンタルヘルス行動計画を推奨しています。また、WHOが発表した主な事実によると、世界中で推定3億人がうつ病に罹患し、6,000万人が双極性障害に罹患しています。不安障害は、子供や大人が罹患する最も一般的な精神疾患です。4400万人のアメリカの成人が不安障害の弊害を経験していると評価されています。不安障害は非常に治療可能であるにもかかわらず、不安障害に苦しんでいる人のわずか約3分の1が治療を受けています。したがって、この市場は、精神障害の有病率の上昇が主な要因であることが示されています。

オランザピンの世界市場の成長は、世界的な統合失調症の有病率の上昇が主な要因です。例えば、2022年1月、世界保健機関（WHO）によると、統合失調症は世界で約2,400万人、300人に1人（0.32%）が罹患しています。また、衛生管理や予防対策の欠如による院内感染（HAI）の増加が、市場成長の主な要因となっています。さらに、精神障害診療所の増加や医療インフラの整備も市場成長に寄与しています。

しかし、オランザピンの高価格と副作用が市場成長の妨げとなっています。逆に、主要企業によるオランザピンの製品承認の増加や、発展途上国における高い成長可能性は、市場プレイヤーに有利な機会を提供すると予想されます。例えば、2021年6月、世界的なバイオ医薬品企業であるAlkermes plc.は、成人の統合失調症の治療薬および成人の双極性Ⅰ型障害の治療薬として、維持療法として、または躁病エピソードまたは混合エピソードの急性期治療薬として、単剤療法またはリチウムもしくはバルプロ酸塩の補助剤として、LYBALVI（オランザピンおよびサミドルファン）が米国食品医薬品局（FDA）の承認を取得しました。

オランザピン市場は、用途、投与経路、流通チャネル、地域に区分されます。用途別では、統合失調症、双極性障害、その他に分類されます。投与経路別では、経口剤と非経口剤に区分されます。流通チャネル別では、病院薬局、ドラッグストア・小売薬局、オンラインプロバイダーに分けられます。地域別では、北米（米国、カナダ、メキシコ）、欧州（ドイツ、フランス、英国、イタリア、スペイン、その他欧州）、アジア太平洋（日本、中国、オーストラリア、インド、韓国、その他アジア太平洋）、LAMEA（ブラジル、南アフリカ、サウジアラビア、その他LAMEA）に市場を分けて分析しています。

世界のオランザピン市場で事業を展開する主な主要企業は、Alkermes、Apotex Inc.、Aurobindo Pharma、Dr. Reddy’s Laboratories Ltd.、Eli Lilly and Company、Novartis AG、Sun Pharmaceutical Industries Ltd.、Teva Pharmaceuticals Industries Ltd.、Torrent Power Ltd.、Viatris Inc.です。

〈ステークホルダーにとっての主なメリット〉
・本レポートは、2021年から2031年までのオランザピン市場分析の市場セグメント、現在の動向、予測、ダイナミクスを定量的に分析し、オランザピン市場の有力な機会を特定します。
・主要な促進要因、阻害要因、機会に関する情報とともに市場調査を提供します。
・ポーターのファイブフォース分析により、バイヤーとサプライヤーの潜在力を明らかにし、ステークホルダーが利益重視のビジネス決定を下し、サプライヤーとバイヤーのネットワークを強化できるようにします。
・オランザピン市場のセグメンテーションを詳細に分析することで、市場機会を見極めることができます。
・オランザピン市場を細分化することで、市場機会を見極めることができます。
・市場プレイヤーのポジショニングはベンチマーキングを容易にし、市場プレイヤーの現在のポジションを明確に理解することができます。
・地域別および世界のオランザピン市場動向、主要企業、市場セグメント、応用分野、市場成長戦略の分析を含みます。

〈主要市場セグメント〉
用途別
双極性障害
統合失調症
その他

投与経路別
経口剤
非経口剤

流通経路別
病院薬局
ドラッグストア＆小売薬局
オンラインプロバイダー

地域別
・北米
米国
カナダ
メキシコ
・ヨーロッパ
ドイツ
フランス
イギリス
イタリア
スペイン
その他のヨーロッパ
・アジア太平洋
日本
中国
インド
オーストラリア
韓国
その他のアジア太平洋地域
・LAMEA
ブラジル
サウジアラビア
南アフリカ
その他のLAMEA地域

〈主要市場プレイヤー〉
Alkermes, Inc.
apotex inc.
Aurobindo Pharma Ltd
Eli Lilly and Company
Dr. Reddy’s Laboratories Ltd.
Sun Pharmaceutical Industries Limited
Torrent Group
Teva Pharmaceutical Industries Limited
Novartis AG
Viatris

世界の市場調査レポート販売サイト（H&Iグローバルリサーチ株式会社運営）
*** レポート目次（コンテンツ）***

CHAPTER 1:INTRODUCTION
1.1.Report description
1.2.Key market segments
1.3.Key benefits to the stakeholders
1.4.Research Methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO Perspective
CHAPTER 3:MARKET OVERVIEW
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.3.Porter’s five forces analysis
3.4.Top player positioning
3.5.Market dynamics
3.5.1.Drivers
3.5.2.Restraints
3.5.3.Opportunities
3.6.COVID-19 Impact Analysis on the market
CHAPTER 4: OLANZAPINE MARKET, BY APPLICATION
4.1 Overview
4.1.1 Market size and forecast
4.2 Schizophrenia
4.2.1 Key market trends, growth factors and opportunities
4.2.2 Market size and forecast, by region
4.2.3 Market share analysis by country
4.3 Bipolar Disorder
4.3.1 Key market trends, growth factors and opportunities
4.3.2 Market size and forecast, by region
4.3.3 Market share analysis by country
4.4 Others
4.4.1 Key market trends, growth factors and opportunities
4.4.2 Market size and forecast, by region
4.4.3 Market share analysis by country
CHAPTER 5: OLANZAPINE MARKET, BY ROUTE OF ADMINISTRATION
5.1 Overview
5.1.1 Market size and forecast
5.2 Oral
5.2.1 Key market trends, growth factors and opportunities
5.2.2 Market size and forecast, by region
5.2.3 Market share analysis by country
5.3 Parenteral
5.3.1 Key market trends, growth factors and opportunities
5.3.2 Market size and forecast, by region
5.3.3 Market share analysis by country
CHAPTER 6: OLANZAPINE MARKET, BY DISTRIBUTION CHANNEL
6.1 Overview
6.1.1 Market size and forecast
6.2 Hospital Pharmacies
6.2.1 Key market trends, growth factors and opportunities
6.2.2 Market size and forecast, by region
6.2.3 Market share analysis by country
6.3 Drug stores and Retail Pharmacies
6.3.1 Key market trends, growth factors and opportunities
6.3.2 Market size and forecast, by region
6.3.3 Market share analysis by country
6.4 Online Providers
6.4.1 Key market trends, growth factors and opportunities
6.4.2 Market size and forecast, by region
6.4.3 Market share analysis by country
CHAPTER 7: OLANZAPINE MARKET, BY REGION
7.1 Overview
7.1.1 Market size and forecast
7.2 North America
7.2.1 Key trends and opportunities
7.2.2 North America Market size and forecast, by Application
7.2.3 North America Market size and forecast, by Route of Administration
7.2.4 North America Market size and forecast, by Distribution Channel
7.2.5 North America Market size and forecast, by country
7.2.5.1 U.S.
7.2.5.1.1 Key market trends, growth factors and opportunities
7.2.5.1.2 Market size and forecast, by Application
7.2.5.1.3 Market size and forecast, by Route of Administration
7.2.5.1.4 Market size and forecast, by Distribution Channel
7.2.5.2 Canada
7.2.5.2.1 Key market trends, growth factors and opportunities
7.2.5.2.2 Market size and forecast, by Application
7.2.5.2.3 Market size and forecast, by Route of Administration
7.2.5.2.4 Market size and forecast, by Distribution Channel
7.2.5.3 Mexico
7.2.5.3.1 Key market trends, growth factors and opportunities
7.2.5.3.2 Market size and forecast, by Application
7.2.5.3.3 Market size and forecast, by Route of Administration
7.2.5.3.4 Market size and forecast, by Distribution Channel
7.3 Europe
7.3.1 Key trends and opportunities
7.3.2 Europe Market size and forecast, by Application
7.3.3 Europe Market size and forecast, by Route of Administration
7.3.4 Europe Market size and forecast, by Distribution Channel
7.3.5 Europe Market size and forecast, by country
7.3.5.1 Germany
7.3.5.1.1 Key market trends, growth factors and opportunities
7.3.5.1.2 Market size and forecast, by Application
7.3.5.1.3 Market size and forecast, by Route of Administration
7.3.5.1.4 Market size and forecast, by Distribution Channel
7.3.5.2 France
7.3.5.2.1 Key market trends, growth factors and opportunities
7.3.5.2.2 Market size and forecast, by Application
7.3.5.2.3 Market size and forecast, by Route of Administration
7.3.5.2.4 Market size and forecast, by Distribution Channel
7.3.5.3 UK
7.3.5.3.1 Key market trends, growth factors and opportunities
7.3.5.3.2 Market size and forecast, by Application
7.3.5.3.3 Market size and forecast, by Route of Administration
7.3.5.3.4 Market size and forecast, by Distribution Channel
7.3.5.4 Italy
7.3.5.4.1 Key market trends, growth factors and opportunities
7.3.5.4.2 Market size and forecast, by Application
7.3.5.4.3 Market size and forecast, by Route of Administration
7.3.5.4.4 Market size and forecast, by Distribution Channel
7.3.5.5 Spain
7.3.5.5.1 Key market trends, growth factors and opportunities
7.3.5.5.2 Market size and forecast, by Application
7.3.5.5.3 Market size and forecast, by Route of Administration
7.3.5.5.4 Market size and forecast, by Distribution Channel
7.3.5.6 Rest of Europe
7.3.5.6.1 Key market trends, growth factors and opportunities
7.3.5.6.2 Market size and forecast, by Application
7.3.5.6.3 Market size and forecast, by Route of Administration
7.3.5.6.4 Market size and forecast, by Distribution Channel
7.4 Asia-Pacific
7.4.1 Key trends and opportunities
7.4.2 Asia-Pacific Market size and forecast, by Application
7.4.3 Asia-Pacific Market size and forecast, by Route of Administration
7.4.4 Asia-Pacific Market size and forecast, by Distribution Channel
7.4.5 Asia-Pacific Market size and forecast, by country
7.4.5.1 Japan
7.4.5.1.1 Key market trends, growth factors and opportunities
7.4.5.1.2 Market size and forecast, by Application
7.4.5.1.3 Market size and forecast, by Route of Administration
7.4.5.1.4 Market size and forecast, by Distribution Channel
7.4.5.2 China
7.4.5.2.1 Key market trends, growth factors and opportunities
7.4.5.2.2 Market size and forecast, by Application
7.4.5.2.3 Market size and forecast, by Route of Administration
7.4.5.2.4 Market size and forecast, by Distribution Channel
7.4.5.3 India
7.4.5.3.1 Key market trends, growth factors and opportunities
7.4.5.3.2 Market size and forecast, by Application
7.4.5.3.3 Market size and forecast, by Route of Administration
7.4.5.3.4 Market size and forecast, by Distribution Channel
7.4.5.4 Australia
7.4.5.4.1 Key market trends, growth factors and opportunities
7.4.5.4.2 Market size and forecast, by Application
7.4.5.4.3 Market size and forecast, by Route of Administration
7.4.5.4.4 Market size and forecast, by Distribution Channel
7.4.5.5 South Korea
7.4.5.5.1 Key market trends, growth factors and opportunities
7.4.5.5.2 Market size and forecast, by Application
7.4.5.5.3 Market size and forecast, by Route of Administration
7.4.5.5.4 Market size and forecast, by Distribution Channel
7.4.5.6 Rest of Asia-Pacific
7.4.5.6.1 Key market trends, growth factors and opportunities
7.4.5.6.2 Market size and forecast, by Application
7.4.5.6.3 Market size and forecast, by Route of Administration
7.4.5.6.4 Market size and forecast, by Distribution Channel
7.5 LAMEA
7.5.1 Key trends and opportunities
7.5.2 LAMEA Market size and forecast, by Application
7.5.3 LAMEA Market size and forecast, by Route of Administration
7.5.4 LAMEA Market size and forecast, by Distribution Channel
7.5.5 LAMEA Market size and forecast, by country
7.5.5.1 Brazil
7.5.5.1.1 Key market trends, growth factors and opportunities
7.5.5.1.2 Market size and forecast, by Application
7.5.5.1.3 Market size and forecast, by Route of Administration
7.5.5.1.4 Market size and forecast, by Distribution Channel
7.5.5.2 Saudi Arabia
7.5.5.2.1 Key market trends, growth factors and opportunities
7.5.5.2.2 Market size and forecast, by Application
7.5.5.2.3 Market size and forecast, by Route of Administration
7.5.5.2.4 Market size and forecast, by Distribution Channel
7.5.5.3 South Africa
7.5.5.3.1 Key market trends, growth factors and opportunities
7.5.5.3.2 Market size and forecast, by Application
7.5.5.3.3 Market size and forecast, by Route of Administration
7.5.5.3.4 Market size and forecast, by Distribution Channel
7.5.5.4 Rest of LAMEA
7.5.5.4.1 Key market trends, growth factors and opportunities
7.5.5.4.2 Market size and forecast, by Application
7.5.5.4.3 Market size and forecast, by Route of Administration
7.5.5.4.4 Market size and forecast, by Distribution Channel
CHAPTER 8: COMPANY LANDSCAPE
8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Key developments
CHAPTER 9: COMPANY PROFILES
9.1 Alkermes, Inc.
9.1.1 Company overview
9.1.2 Company snapshot
9.1.3 Operating business segments
9.1.4 Product portfolio
9.1.5 Business performance
9.1.6 Key strategic moves and developments
9.2 apotex inc.
9.2.1 Company overview
9.2.2 Company snapshot
9.2.3 Operating business segments
9.2.4 Product portfolio
9.2.5 Business performance
9.2.6 Key strategic moves and developments
9.3 Aurobindo Pharma Ltd
9.3.1 Company overview
9.3.2 Company snapshot
9.3.3 Operating business segments
9.3.4 Product portfolio
9.3.5 Business performance
9.3.6 Key strategic moves and developments
9.4 Eli Lilly and Company
9.4.1 Company overview
9.4.2 Company snapshot
9.4.3 Operating business segments
9.4.4 Product portfolio
9.4.5 Business performance
9.4.6 Key strategic moves and developments
9.5 Dr. Reddy’s Laboratories Ltd.
9.5.1 Company overview
9.5.2 Company snapshot
9.5.3 Operating business segments
9.5.4 Product portfolio
9.5.5 Business performance
9.5.6 Key strategic moves and developments
9.6 Sun Pharmaceutical Industries Limited
9.6.1 Company overview
9.6.2 Company snapshot
9.6.3 Operating business segments
9.6.4 Product portfolio
9.6.5 Business performance
9.6.6 Key strategic moves and developments
9.7 Torrent Group
9.7.1 Company overview
9.7.2 Company snapshot
9.7.3 Operating business segments
9.7.4 Product portfolio
9.7.5 Business performance
9.7.6 Key strategic moves and developments
9.8 Teva Pharmaceutical Industries Limited
9.8.1 Company overview
9.8.2 Company snapshot
9.8.3 Operating business segments
9.8.4 Product portfolio
9.8.5 Business performance
9.8.6 Key strategic moves and developments
9.9 Novartis AG
9.9.1 Company overview
9.9.2 Company snapshot
9.9.3 Operating business segments
9.9.4 Product portfolio
9.9.5 Business performance
9.9.6 Key strategic moves and developments
9.10 Viatris
9.10.1 Company overview
9.10.2 Company snapshot
9.10.3 Operating business segments
9.10.4 Product portfolio
9.10.5 Business performance
9.10.6 Key strategic moves and developments

LIST OF TABLES
TABLE 1. GLOBAL OLANZAPINE MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 2. OLANZAPINE MARKET FOR SCHIZOPHRENIA, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 3. OLANZAPINE MARKET FOR SCHIZOPHRENIA, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 4. OLANZAPINE MARKET FOR BIPOLAR DISORDER, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 5. OLANZAPINE MARKET FOR BIPOLAR DISORDER, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 6. OLANZAPINE MARKET FOR OTHERS, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 7. OLANZAPINE MARKET FOR OTHERS, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 8. GLOBAL OLANZAPINE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
TABLE 9. OLANZAPINE MARKET FOR ORAL, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 10. OLANZAPINE MARKET FOR ORAL, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 11. OLANZAPINE MARKET FOR PARENTERAL, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 12. OLANZAPINE MARKET FOR PARENTERAL, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 13. GLOBAL OLANZAPINE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 14. OLANZAPINE MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 15. OLANZAPINE MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 16. OLANZAPINE MARKET FOR DRUG STORES AND RETAIL PHARMACIES, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 17. OLANZAPINE MARKET FOR DRUG STORES AND RETAIL PHARMACIES, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 18. OLANZAPINE MARKET FOR ONLINE PROVIDERS, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 19. OLANZAPINE MARKET FOR ONLINE PROVIDERS, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 20. OLANZAPINE MARKET, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 21. NORTH AMERICA OLANZAPINE MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 22. NORTH AMERICA OLANZAPINE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
TABLE 23. NORTH AMERICA OLANZAPINE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 24. NORTH AMERICA OLANZAPINE MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 25. U.S. OLANZAPINE MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 26. U.S. OLANZAPINE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
TABLE 27. U.S. OLANZAPINE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 28. CANADA OLANZAPINE MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 29. CANADA OLANZAPINE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
TABLE 30. CANADA OLANZAPINE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 31. MEXICO OLANZAPINE MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 32. MEXICO OLANZAPINE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
TABLE 33. MEXICO OLANZAPINE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 34. EUROPE OLANZAPINE MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 35. EUROPE OLANZAPINE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
TABLE 36. EUROPE OLANZAPINE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 37. EUROPE OLANZAPINE MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 38. GERMANY OLANZAPINE MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 39. GERMANY OLANZAPINE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
TABLE 40. GERMANY OLANZAPINE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 41. FRANCE OLANZAPINE MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 42. FRANCE OLANZAPINE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
TABLE 43. FRANCE OLANZAPINE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 44. UK OLANZAPINE MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 45. UK OLANZAPINE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
TABLE 46. UK OLANZAPINE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 47. ITALY OLANZAPINE MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 48. ITALY OLANZAPINE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
TABLE 49. ITALY OLANZAPINE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 50. SPAIN OLANZAPINE MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 51. SPAIN OLANZAPINE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
TABLE 52. SPAIN OLANZAPINE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 53. REST OF EUROPE OLANZAPINE MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 54. REST OF EUROPE OLANZAPINE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
TABLE 55. REST OF EUROPE OLANZAPINE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 56. ASIA-PACIFIC OLANZAPINE MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 57. ASIA-PACIFIC OLANZAPINE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
TABLE 58. ASIA-PACIFIC OLANZAPINE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 59. ASIA-PACIFIC OLANZAPINE MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 60. JAPAN OLANZAPINE MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 61. JAPAN OLANZAPINE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
TABLE 62. JAPAN OLANZAPINE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 63. CHINA OLANZAPINE MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 64. CHINA OLANZAPINE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
TABLE 65. CHINA OLANZAPINE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 66. INDIA OLANZAPINE MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 67. INDIA OLANZAPINE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
TABLE 68. INDIA OLANZAPINE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 69. AUSTRALIA OLANZAPINE MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 70. AUSTRALIA OLANZAPINE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
TABLE 71. AUSTRALIA OLANZAPINE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 72. SOUTH KOREA OLANZAPINE MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 73. SOUTH KOREA OLANZAPINE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
TABLE 74. SOUTH KOREA OLANZAPINE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 75. REST OF ASIA-PACIFIC OLANZAPINE MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 76. REST OF ASIA-PACIFIC OLANZAPINE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
TABLE 77. REST OF ASIA-PACIFIC OLANZAPINE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 78. LAMEA OLANZAPINE MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 79. LAMEA OLANZAPINE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
TABLE 80. LAMEA OLANZAPINE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 81. LAMEA OLANZAPINE MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 82. BRAZIL OLANZAPINE MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 83. BRAZIL OLANZAPINE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
TABLE 84. BRAZIL OLANZAPINE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 85. SAUDI ARABIA OLANZAPINE MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 86. SAUDI ARABIA OLANZAPINE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
TABLE 87. SAUDI ARABIA OLANZAPINE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 88. SOUTH AFRICA OLANZAPINE MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 89. SOUTH AFRICA OLANZAPINE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
TABLE 90. SOUTH AFRICA OLANZAPINE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 91. REST OF LAMEA OLANZAPINE MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 92. REST OF LAMEA OLANZAPINE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
TABLE 93. REST OF LAMEA OLANZAPINE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 94.ALKERMES, INC.: COMPANY SNAPSHOT
TABLE 95.ALKERMES, INC.: OPERATING SEGMENTS
TABLE 96.ALKERMES, INC.: PRODUCT PORTFOLIO
TABLE 97.ALKERMES, INC.: NET SALES
TABLE 98.ALKERMES, INC.: KEY STRATERGIES
TABLE 99.APOTEX INC.: COMPANY SNAPSHOT
TABLE 100.APOTEX INC.: OPERATING SEGMENTS
TABLE 101.APOTEX INC.: PRODUCT PORTFOLIO
TABLE 102.APOTEX INC.: NET SALES
TABLE 103.APOTEX INC.: KEY STRATERGIES
TABLE 104.AUROBINDO PHARMA LTD: COMPANY SNAPSHOT
TABLE 105.AUROBINDO PHARMA LTD: OPERATING SEGMENTS
TABLE 106.AUROBINDO PHARMA LTD: PRODUCT PORTFOLIO
TABLE 107.AUROBINDO PHARMA LTD: NET SALES
TABLE 108.AUROBINDO PHARMA LTD: KEY STRATERGIES
TABLE 109.ELI LILLY AND COMPANY: COMPANY SNAPSHOT
TABLE 110.ELI LILLY AND COMPANY: OPERATING SEGMENTS
TABLE 111.ELI LILLY AND COMPANY: PRODUCT PORTFOLIO
TABLE 112.ELI LILLY AND COMPANY: NET SALES
TABLE 113.ELI LILLY AND COMPANY: KEY STRATERGIES
TABLE 114.DR. REDDY'S LABORATORIES LTD.: COMPANY SNAPSHOT
TABLE 115.DR. REDDY'S LABORATORIES LTD.: OPERATING SEGMENTS
TABLE 116.DR. REDDY'S LABORATORIES LTD.: PRODUCT PORTFOLIO
TABLE 117.DR. REDDY'S LABORATORIES LTD.: NET SALES
TABLE 118.DR. REDDY'S LABORATORIES LTD.: KEY STRATERGIES
TABLE 119.SUN PHARMACEUTICAL INDUSTRIES LIMITED: COMPANY SNAPSHOT
TABLE 120.SUN PHARMACEUTICAL INDUSTRIES LIMITED: OPERATING SEGMENTS
TABLE 121.SUN PHARMACEUTICAL INDUSTRIES LIMITED: PRODUCT PORTFOLIO
TABLE 122.SUN PHARMACEUTICAL INDUSTRIES LIMITED: NET SALES
TABLE 123.SUN PHARMACEUTICAL INDUSTRIES LIMITED: KEY STRATERGIES
TABLE 124.TORRENT GROUP: COMPANY SNAPSHOT
TABLE 125.TORRENT GROUP: OPERATING SEGMENTS
TABLE 126.TORRENT GROUP: PRODUCT PORTFOLIO
TABLE 127.TORRENT GROUP: NET SALES
TABLE 128.TORRENT GROUP: KEY STRATERGIES
TABLE 129.TEVA PHARMACEUTICAL INDUSTRIES LIMITED: COMPANY SNAPSHOT
TABLE 130.TEVA PHARMACEUTICAL INDUSTRIES LIMITED: OPERATING SEGMENTS
TABLE 131.TEVA PHARMACEUTICAL INDUSTRIES LIMITED: PRODUCT PORTFOLIO
TABLE 132.TEVA PHARMACEUTICAL INDUSTRIES LIMITED: NET SALES
TABLE 133.TEVA PHARMACEUTICAL INDUSTRIES LIMITED: KEY STRATERGIES
TABLE 134.NOVARTIS AG: COMPANY SNAPSHOT
TABLE 135.NOVARTIS AG: OPERATING SEGMENTS
TABLE 136.NOVARTIS AG: PRODUCT PORTFOLIO
TABLE 137.NOVARTIS AG: NET SALES
TABLE 138.NOVARTIS AG: KEY STRATERGIES
TABLE 139.VIATRIS: COMPANY SNAPSHOT
TABLE 140.VIATRIS: OPERATING SEGMENTS
TABLE 141.VIATRIS: PRODUCT PORTFOLIO
TABLE 142.VIATRIS: NET SALES
TABLE 143.VIATRIS: KEY STRATERGIES

*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
※関連調査資料
  • メンタルヘルスのグローバル市場：統合失調症、アルコール使用障害、双極性障害、うつ病＆不安症、その他
  • 世界のメンタルヘルス市場予測2024年-2032年：疾患別（統合失調症、アルコール使用障害、双極性障害、うつ病と不安障害、心的外傷後ストレス障害、薬物乱用障害、摂食障害、その他）、サービス別（緊急メンタルヘルスサービス、外来カウンセリング、在宅治療サービス、入院治療サービス、その他）、年齢層別（小児、成人、老人）、地域別
  • ペプチド治療薬のグローバル市場（2021〜2031）：代謝、腫瘍、胃腸、神経、心血管、その他
  • トキソプラズマ症治療のグローバル市場（2021〜2031）：後天性トキソプラズマ症、先天性トキソプラズマ症
    • ※注目の調査資料
     ※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
    ※当市場調査資料(ALD23FB147 )"オランザピンのグローバル市場（2021〜2031）：統合失調症、双極性障害、その他" (英文：Olanzapine Market By Application (Schizophrenia, Bipolar Disorder, Others), By Route of Administration (Oral, Parenteral), By Distribution Channel (Hospital Pharmacies, Drug stores and Retail Pharmacies, Online Providers): Global Opportunity Analysis and Industry Forecast, 2021-2031)はAllied Market Research社が調査・発行しており、H&Iグローバルリサーチが販売します。

    ◆H&Iグローバルリサーチのお客様（例）◆


    ※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
    ※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。